

## Second Generation API Process Development in Pfizer Ireland

The Pfizer philosophy towards the development of second generation (small molecule) API processes will be outlined. Once a synthetic process for an API has been filed with regulatory authorities, there exist major barriers towards filing of an alternative process. The talk will outline the rationale, constraints and opportunities in developing and filing a next generation process using a recent case study.